AU2007204831B2 - Compounds and methods for the treatment of cancer - Google Patents

Compounds and methods for the treatment of cancer Download PDF

Info

Publication number
AU2007204831B2
AU2007204831B2 AU2007204831A AU2007204831A AU2007204831B2 AU 2007204831 B2 AU2007204831 B2 AU 2007204831B2 AU 2007204831 A AU2007204831 A AU 2007204831A AU 2007204831 A AU2007204831 A AU 2007204831A AU 2007204831 B2 AU2007204831 B2 AU 2007204831B2
Authority
AU
Australia
Prior art keywords
cancer
compound
hours
therapy
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007204831A
Other languages
English (en)
Other versions
AU2007204831A1 (en
Inventor
Ralph A. Zingaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Original Assignee
Texas A&M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System filed Critical Texas A&M University System
Publication of AU2007204831A1 publication Critical patent/AU2007204831A1/en
Application granted granted Critical
Publication of AU2007204831B2 publication Critical patent/AU2007204831B2/en
Priority to AU2013273809A priority Critical patent/AU2013273809A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/80—Heterocyclic compounds
    • C07F9/82—Arsenic compounds containing one or more pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007204831A 2006-01-13 2007-01-16 Compounds and methods for the treatment of cancer Ceased AU2007204831B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013273809A AU2013273809A1 (en) 2006-01-13 2013-12-21 Compounds and methods for the treatment of cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75921806P 2006-01-13 2006-01-13
US60/759,218 2006-01-13
US76300806P 2006-01-26 2006-01-26
US60/763,008 2006-01-26
PCT/US2007/001127 WO2007082104A2 (en) 2006-01-13 2007-01-16 Compounds and methods for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013273809A Division AU2013273809A1 (en) 2006-01-13 2013-12-21 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2007204831A1 AU2007204831A1 (en) 2007-07-19
AU2007204831B2 true AU2007204831B2 (en) 2013-10-03

Family

ID=38158019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007204831A Ceased AU2007204831B2 (en) 2006-01-13 2007-01-16 Compounds and methods for the treatment of cancer

Country Status (10)

Country Link
US (2) US8222440B2 (https=)
EP (1) EP1979368B1 (https=)
JP (1) JP5202332B2 (https=)
KR (2) KR20130129316A (https=)
CN (2) CN104109177A (https=)
AU (1) AU2007204831B2 (https=)
CA (1) CA2636793C (https=)
HK (1) HK1203512A1 (https=)
IL (3) IL192738A0 (https=)
WO (1) WO2007082104A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG186599A1 (en) * 2007-12-12 2013-01-30 Ziopharm Oncology Inc Compounds and methods for the treatment of cancer
RU2534606C2 (ru) 2008-08-20 2014-11-27 Зайофарм Онколоджи, Инк. Мышьякорганические соединения и способы лечения рака
TWI617305B (zh) * 2013-12-05 2018-03-11 蘇愛康制藥有限公司 治療癌症的化合物及其應用程序

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057012A2 (en) * 2002-01-07 2003-07-17 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
WO2006020048A2 (en) * 2004-07-16 2006-02-23 The Texas A & M University System Compounds and methods for treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057012A2 (en) * 2002-01-07 2003-07-17 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
WO2006020048A2 (en) * 2004-07-16 2006-02-23 The Texas A & M University System Compounds and methods for treatment of cancer

Also Published As

Publication number Publication date
IL226362A0 (en) 2013-06-27
US8222440B2 (en) 2012-07-17
CA2636793C (en) 2014-07-08
HK1203512A1 (en) 2015-10-30
CA2636793A1 (en) 2007-07-19
WO2007082104A2 (en) 2007-07-19
AU2007204831A1 (en) 2007-07-19
HK1130804A1 (en) 2010-01-08
EP1979368B1 (en) 2014-12-24
US20130143950A1 (en) 2013-06-06
US20090233894A1 (en) 2009-09-17
WO2007082104A3 (en) 2007-10-18
JP2009527463A (ja) 2009-07-30
CN101395166B (zh) 2014-07-09
IL226363A0 (en) 2013-06-27
KR101471498B1 (ko) 2014-12-10
JP5202332B2 (ja) 2013-06-05
IL192738A0 (en) 2009-02-11
EP1979368A2 (en) 2008-10-15
CN104109177A (zh) 2014-10-22
KR20080106897A (ko) 2008-12-09
KR20130129316A (ko) 2013-11-27
CN101395166A (zh) 2009-03-25

Similar Documents

Publication Publication Date Title
AU2005274926B2 (en) Compounds and methods for treatment of cancer
US8334398B2 (en) Compounds and methods for the treatment of cancer
US11324714B2 (en) Organoarsenic compounds and methods for the treatment of cancer
AU2007204831B2 (en) Compounds and methods for the treatment of cancer
AU2013273809A1 (en) Compounds and methods for the treatment of cancer
US20160304546A1 (en) Compounds and methods for the treatment of cancer
HK1130804B (en) Compounds and methods for the treatment of cancer
AU2013270520A1 (en) Compounds and methods for treatment of cancer
HK1164767B (en) Compounds and methods for the treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired